1. South Africa Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Adcock Ingram Holdings Limited

Adcock Ingram Holdings Limited

AIHLF
Adcock Ingram Holdings LimitedUS flagOther OTC
3.50
USD
- -
- -
624.32MMarket Cap
2012 Y
2013 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
27.23
30.81
30.56
33.31
35.7
38.38
42.57
43.23
46.88
53.82
57.05
63.93
66.5
Basic EPS, GAAP
4.18
3.49
1.17
1.01
3.33
3.84
4.14
3.98
3.96
4.95
5.61
5.4
5.85
Free Cash Flow per Basic Share
-0.4
-2.23
2.06
2.56
1.33
1
1.75
2.18
0.42
2.02
1.46
2.9
0.95
Dividend per Share
1.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
14.92
16.41
11.84
11.61
15.76
18.17
20.66
22.17
25.52
29.18
32.71
37.59
41.66
Tangible Book Value per Share
16.8
13.81
14.06
17.89
18.91
19.78
22.19
21.24
21.88
24.74
25.96
28.5
31.84
Basic Weighted Avg Shares
169
169
169
166
166
166
166
170
166
162
160
151
147
Sales/Revenue/Turnover
4,599
5,195
5,159
5,546
5,936
6,383
7,078
7,347
7,777
8,706
9,132
9,643
9,760
Operating Margin (%)
18.89
14.93
9.75
10.2
11.52
12.78
12.91
12.84
11.53
12.31
12.44
12.29
11.74
Depreciation Expense
- -
185
196
148
150
169
164
195
195
234
198
201
212
Net Income, GAAP
706
588
198
169
554
638
688
676
657
800
898
814
859
Effective Tax Rate (%)
18.96
26.33
28.85
31.01
28.26
27.99
27.88
26.65
26.91
27.34
25.48
27.63
24.81
Profit Margin (%)
15.34
11.32
3.84
3.04
9.32
9.99
9.72
9.21
8.45
9.19
9.84
8.44
8.8
Working Capital
1,317
462
1,119
1,712
1,600
1,397
1,724
1,671
1,768
2,159
2,180
2,355
2,695
LT Debt
101
5
514
500
251
- -
- -
281
247
310
280
238
198
Total Equity
3,549
3,764
3,117
3,255
3,495
3,915
4,298
4,539
4,683
5,245
5,388
5,413
5,833
Return on Invested Capital (%)
17.34
12.29
7.81
10.22
13.22
15.08
15.65
15.12
13.38
14.75
14.95
14.95
14.58
Return on Capital (%)
23.48
16.96
7.25
7.77
21.29
21.05
20.66
18.59
15.98
17.38
17.76
15.37
15.4
Return on Common Equity (%)
31.58
22.24
8.31
8.58
24.31
22.61
21.31
18.78
16.43
17.88
18.05
14.93
14.57

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.53%
5.23%
7.77%
Free Cash Flow
33.31%
56.18%
-68.14%
Net Income, GAAP
26.19%
5.45%
5.47%
Sales/Revenue/Turnover
6.63%
5.9%
1.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
9,132
2024
- -
- -
- -
- -
9,643
2025
- -
- -
- -
- -
9,760

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5.61
2024
- -
- -
- -
- -
5.4
2025
- -
- -
- -
- -
5.85

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Andrew Gideon Hall
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
1 New Road Midrand South Africa 1682
IPO Date
Jun 12, 2014
Website
adcock.co.za
Similar Companies
Fuji Pharma Co., Ltd. (4554.T)
PT Phapros, Tbk (PEHA.JK)
Unichem Laboratories Limited (UNICHEMLAB.NS)
Alpa Laboratories Limited (ALPA.NS)
Elanco Animal Health Incorporated (ELAN)
TerrAscend Corp. (TSND.TO)
Business
Adcock Ingram Holdings Limited manufactures, markets and distributes a broad portfolio of pharmaceutical, over-the-counter, consumer healthcare and hospital products primarily in South Africa. The company operates through five main segments: Consumer, which supplies fast-moving consumer goods including personal care and homecare items through retailers and pharmacies; Over-the-Counter (OTC), featuring brands sold mainly in pharmacies; Prescription, offering products prescribed by medical practitioners along with specialized instruments and surgical items; Hospital, providing critical care solutions such as intravenous fluids, blood collection products, renal dialysis systems, injectables and nutrition ranges; and Other, encompassing shared services, regulatory operations in India and joint venture investments. Founded in 1890 and headquartered in Midrand, South Africa, Adcock Ingram maintains three production sites in South Africa and one in India, serving private sector customers with a focus on generic and branded medicines across Southern Africa. In 2025, the company advances a major strategic shift through Natco Pharma's acquisition of a significant stake valued at R4.2 billion, positioning it as a privately held entity co-owned by Natco to enhance generics expansion, leverage R&D expertise and broaden access to affordable medicines in emerging markets. Fiscal year 2025 results show revenue growth of 1% to ZAR9.8 billion, headline earnings per share up 1.5% and consumer division trading profit rising 6%, supported by joint venture contributions and share buybacks.